Comparison · 8 min read
Clascoterone vs finasteride
Different targets. Different evidence maturity. Different side-effect conversations. Not interchangeable.
Mechanism
| Finasteride 1 mg | Clascoterone 5% solution | |
|---|---|---|
| Target | Type II 5-alpha-reductase | Androgen receptor in skin |
| DHT in blood | Falls substantially | Designed not to |
| Route | Oral, once daily | Topical, twice daily (trial regimen) |
| Regulatory status for AGA | Approved for decades | Investigational (Aug 2026) |
Evidence grade
Finasteride has 25+ years of randomised data, meta-analyses, and real-world series. You know the effect size range, the sexual-side-effect incidence debates, and what happens at year five.
Clascoterone has a completed Phase 3 programme and 12-month extension topline. That is promising and large (n=1,465). It is not yet a substitute for the finasteride literature. There is no published head-to-head.
Side effects — the real fork
Men avoid finasteride because of sexual dysfunction, brain-fog anecdotes, and “post-finasteride” discourse. Population-level rates are lower than forum culture implies; individual risk is not zero. Clascoterone’s pitch is: keep the anti-androgen effect inside the follicle. If the full safety package holds, that is the product.
Topicals create their own burden: twice-daily application, vehicle residue, contact dermatitis. A pill you forget is still a pill. A solution you skip is zero receptor occupancy that day.
Who might prefer which
- Stay on finasteride if you already tolerate it and are stable. Do not abandon a working systemic for an unapproved topical.
- Watch clascoterone if you refused orals, had side effects, or want a topical anti-androgen to pair with minoxidil later.
- Do not stack blindly. Combining a 5-ARI with a topical AR blocker is biologically coherent and clinically unproven at scale.
For something you can start this week, see current options.